Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) shares saw an uptick in trading volume on Thursday . 5,773 shares were traded during trading, a decline of 15% from the previous session’s volume of 6,823 shares.The stock last traded at $17.45 and had previously closed at $16.81.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the company. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective for the company. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat.com, Ascentage Pharma Group International has an average rating of “Buy” and a consensus target price of $46.43.
Read Our Latest Stock Report on Ascentage Pharma Group International
Ascentage Pharma Group International Price Performance
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million for the quarter. Equities analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.
Institutional Trading of Ascentage Pharma Group International
Several institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the third quarter worth about $383,000. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the second quarter worth about $391,000. Finally, UBS Group AG boosted its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter.
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.
Founded in 2008 by biotechnology entrepreneur Dr.
Featured Articles
- Five stocks we like better than Ascentage Pharma Group International
- One of Trump’s Favorite Stocks Just Reported Blowout Earnings
- Amazon’s Robot Push Raises a Bigger Question About Its Next Margin Lever
- Palo Alto Networks Is Expensive—But Its Growth Is Accelerating
- AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone Opportunity
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
